BRAIN

Currently No Open Clinical Trials

BREAST

(Neoadjuvant)

Currently No Open Clinical Trials

(Adjuvant Stage I - III)

SWOG 0221 - A Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node Positive or High-Risk Node Negative Breast Cancer.

SWOG 0230 - Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.

SWOG 0307 - Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

(Metastatic)

SWOG 0226 - Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer.  

SWOG 0500 - Phase III Randomized Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment  

GASTROINTESTINAL

(Anal)

Currently No Open Clinical Trials

(Advanced Pancreas Cancer)

Currently No Open Clinical Trials

(Mestastatic Esophageal)

Currently No Open Clinical Trials

GENITOURINARY

GYNECOLOGY

GOG 0212 - A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND#70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Preitoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.

HEAD AND NECK

SWOG 0618 - Phase II Evaluation of E7389 (NSC-707389) in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

LUNG

(Small Cell Lung Cancer - SCLC)

Currently No Open Clinical Trials

(Non-Small Cell Lung Cancer - NSCLC)

SWOG 0429 - A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer.

SWOG 0536 - A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer.

(Ancillary)

SWOG 9925 - Lung Cancer Specimen Repository Protocol, Ancillary.

(BAC)

SWOG 0526 - Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC).

(Mesothelioma)

SWOG 0509 - A Phase II Study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma.

LYMPHOMA

(Non-Hodgkin's)

SWOG 0016 - A Phase III Trial of CHOP + Rituximab VS. CHOP + Iodine - 131- Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma's.

SWOG 0313 - Evaluation of CHOP Plus Involved Field Radiotherapy Followed by YTTRIUM-90 IBRITUMOMAB TIUXETAN For Stages 1, 1E, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II.

SWOG 0433 - Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients > or = to Age 60 with Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study.

SWOG 0515 -Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL.

SWOG 0520 - Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lumphomas.

(Hodgkin's)

Currently No Open Clinical Trials

(Central)

SWOG 8819 - Central Lymphoma Repository Tissue Procurement Protocol.

SWOG 8947 - Central Lymphoma Serum Repository Protocol.

SWOG 9245 - Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary.

(Mantle Cell)

SWOG 0601 - A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients with Newly Diagnosed Mantle Cell Lymphoma.

MELANOMA

Currently No Open Clinical Trials

MYELOMA

SWOG 0434 - A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma Previously Treated with Bortezomib.

UARK 2003-33 - A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

(Ancillary)

SWOG 0309 - Myeloma Specimen Repository Protocol, Ancillary.